https://finance.yahoo.com/news/adial-pharmaceuticals-enters-common-stock-143000204.html
over $7 million of cash on hand as of September 30, 2020;
"We decided to enter into this agreement with Keystone as we believe they have a strong fundamental understanding our business,
and are an ideal strategic partner to support any financial needs that may arise," said William Stilley, CEO of Adial Pharmaceuticals.
"We have no immediate plans to raise capital, with over $7 million of cash on hand as of September 30, 2020;
however, this transaction provides additional flexibility and capability to take advantage of strategic opportunities and future growth initiatives when they may arise."
"We are pleased to enter into this relationship with Adial," said Fred Zaino, Managing Partner and Chief Investment Officer of Keystone.
"After evaluating Adial, its clinical pipeline, and its management team, and after thorough due diligence, we believe Adial represents a promising investment opportunity.
Formation of this partnership memorializes our intention to build a long-term relationship with Adial, committing
capital as necessary as the Company builds its business in the growing space of addiction that is currently woefully underserved."
Recent ADIL News
- Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder • GlobeNewswire Inc. • 09/19/2024 12:30:00 PM
- Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/04/2024 01:00:00 PM
- Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/14/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:13:57 PM
- Adial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04 • GlobeNewswire Inc. • 08/13/2024 01:00:00 PM
- Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder • GlobeNewswire Inc. • 08/07/2024 01:00:00 PM
- Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044 • GlobeNewswire Inc. • 07/31/2024 12:30:00 PM
- Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder • GlobeNewswire Inc. • 07/23/2024 12:30:00 PM
- Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder • GlobeNewswire Inc. • 06/20/2024 12:30:00 PM
- Adial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder • GlobeNewswire Inc. • 06/05/2024 12:30:00 PM
- Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th • GlobeNewswire Inc. • 05/29/2024 12:30:00 PM
- Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/15/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 09:03:18 PM
- Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office • GlobeNewswire Inc. • 04/22/2024 12:30:00 PM
- Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder • GlobeNewswire Inc. • 04/10/2024 12:30:00 PM
- Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update • GlobeNewswire Inc. • 04/02/2024 12:30:00 PM
- Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds • GlobeNewswire Inc. • 03/02/2024 12:00:00 AM
- Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office • GlobeNewswire Inc. • 02/28/2024 02:30:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:22:13 PM
- Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office • GlobeNewswire Inc. • 02/13/2024 02:15:24 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/25/2024 09:30:56 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/25/2024 05:15:07 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 09:15:23 PM
- Adial Announces Appointment of Tony Goodman as Chief Operating Officer • GlobeNewswire Inc. • 01/18/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 09:17:10 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM